Last updated: September 9, 2026
Indacaterol maleate is a once-daily long-acting beta2-agonist (LABA) used primarily in chronic obstructive pulmonary disease (COPD). Its commercial value shifted from the standalone product Arcapta Neohaler and Onbrez Breezhaler to fixed-dose combinations, especially indacaterol/glycopyrronium and indacaterol/glycopyrronium/mometasone. The product has strong pharmacologic differentiation through once-daily dosing, but its commercial position has weakened because of crowded LABA/LAMA markets, generic competition against older inhaled therapies, patent maturation, and limited US market penetration.
Indacaterol is no longer a major standalone growth product. Its continuing value is concentrated in combination inhalers and geographic markets where Novartis maintains respiratory operations.
What is indacaterol maleate and how is it marketed?
Indacaterol maleate is the maleate salt of indacaterol, an ultra-long-acting selective beta2-adrenergic agonist. It relaxes bronchial smooth muscle and provides approximately 24-hour bronchodilation after once-daily inhalation.
| Product |
Active ingredients |
Primary indication |
Key market |
| Arcapta Neohaler |
Indacaterol maleate |
COPD maintenance |
United States |
| Onbrez Breezhaler |
Indacaterol maleate |
COPD maintenance |
Europe and international markets |
| Utibron Neohaler |
Indacaterol/glycopyrrolate |
COPD maintenance |
United States |
| Ultibro Breezhaler |
Indacaterol/glycopyrronium |
COPD maintenance |
Europe and international markets |
| Atectura Breezhaler |
Indacaterol/mometasone |
Asthma maintenance |
Europe and selected markets |
| Enerzair Breezhaler |
Indacaterol/glycopyrronium/mometasone |
Asthma maintenance |
Europe and selected markets |
The US Food and Drug Administration approved Arcapta Neohaler in July 2011. It approved Utibron Neohaler, the indacaterol/glycopyrrolate combination, in October 2015. The European Medicines Agency authorized Onbrez Breezhaler in 2009 and Ultibro Breezhaler in 2013. The European approval of the triple combination extended indacaterol into asthma treatment through a different clinical and regulatory pathway. [1-4]
Indacaterol is not approved as a rescue bronchodilator. Its labeling requires use as maintenance therapy and warns against use for acute bronchospasm. [1]
What is the FDA and regulatory status of indacaterol products?
The US commercial position is materially weaker than the European position.
Arcapta Neohaler received FDA approval for once-daily COPD maintenance treatment, but its US commercial life was limited. Novartis later transferred US rights for Arcapta, Utibron, and Seebri to Sun Pharmaceutical Industries. The transaction reflected a portfolio rationalization rather than a major investment in US respiratory growth. [5]
The European and international markets remain more important for indacaterol because the Breezhaler platform supports multiple products:
- Onbrez for LABA monotherapy.
- Ultibro for LABA/LAMA dual bronchodilation.
- Atectura and Enerzair for inhaled corticosteroid-containing asthma treatment.
- Additional regional products using the same inhaler technology and molecule combinations.
The regulatory trajectory therefore moved from a single-molecule COPD product toward lifecycle management through fixed-dose combinations. This reduced dependence on indacaterol monotherapy but also exposed the franchise to direct competition from other LABA/LAMA and triple-therapy inhalers.
When does indacaterol lose exclusivity?
Indacaterol’s exclusivity position depends on the product, jurisdiction, patent family, formulation, inhaler device, and combination claims.
United States
The original US exclusivity period for Arcapta was five years from FDA approval, subject to the applicable new chemical entity rules. That period expired in 2016. Any remaining US protection therefore depended primarily on patents covering the active ingredient, inhaled formulation, capsule, device, or method of treatment.
The principal commercial risk is not a single universal expiration date. Different claims can expire at different times, and generic or authorized-generic entry can target the drug, the inhaler, or both. The FDA Orange Book remains the controlling source for listed patents and regulatory exclusivity for approved US products. [6]
Arcapta’s US position is further weakened by the absence of a large branded commercial base. Even where patent protection remains relevant, a generic launch may have limited effect on current branded revenue because the US product has already undergone substantial commercial contraction.
Europe and international markets
European patent expiry is country-specific. Supplementary protection certificates, national validations, pediatric extensions, and local litigation can change the effective date. The key commercial distinction is that indacaterol is often sold in combination products, so expiry of a monotherapy patent does not automatically remove protection from every indacaterol-containing product.
The relevant patent categories include:
| Protection category |
Commercial purpose |
| Active compound claims |
Protect indacaterol or related chemical structures |
| Salt claims |
Cover indacaterol maleate and pharmaceutical salt forms |
| Inhaled formulation claims |
Protect powder composition, carrier particles, and dose delivery |
| Capsule claims |
Protect the single-dose capsule used in Breezhaler or Neohaler systems |
| Device claims |
Protect inhaler geometry, piercing, airflow, and dose dispersion |
| Combination claims |
Protect indacaterol with glycopyrronium, glycopyrrolate, or mometasone |
| Method-of-use claims |
Cover once-daily COPD or asthma treatment and patient subgroups |
The practical exclusivity cliff is therefore staggered. Generic pressure can begin when compound or formulation claims expire, while device and combination claims may continue to complicate substitution.
How many patents cover indacaterol maleate?
No single global patent count accurately describes the estate. The portfolio includes international priority families, national members, continuations, divisionals, patent-term adjustments, and combination-product filings.
The estate is best analyzed in four layers:
- Early composition-of-matter and substituted chemical compound patents.
- Salt, formulation, and inhalation-powder patents.
- Breezhaler and Neohaler device and capsule patents.
- Combination patents for Ultibro, Utibron, Atectura, and Enerzair.
The strongest early protection was associated with the active compound and commercial inhalation technology. Later filings had narrower scope and greater vulnerability to invalidity challenges because they focused on specific formulations, dose strengths, devices, or combinations.
Patent strength is moderate rather than absolute. Indacaterol has meaningful technical barriers in inhaled delivery, but the molecule is a small chemical entity and does not benefit from the high manufacturing and regulatory barriers associated with biologics. Patent disputes can also be designed around separate components. A generic sponsor may challenge the active ingredient, use a different inhaler, or pursue a non-infringing formulation.
What generic entry risks exist for indacaterol?
Generic entry risk is higher in the United States than in Europe for the standalone product, but the timing and commercial impact differ by product.
Standalone indacaterol
Standalone indacaterol is exposed to:
- Expired new chemical entity exclusivity.
- Maturing compound and formulation patents.
- Low prescriber dependence on the Arcapta brand.
- Substitution by generic LABA and LAMA therapies.
- Limited willingness among payers to preserve premium pricing.
An abbreviated new drug application could face device-equivalence requirements if the applicant uses a comparable inhaler. A different device may require separate demonstration of dose delivery, labeling, and substitutability. This can delay entry but does not create a durable biologic-style barrier.
Combination products
Indacaterol/glycopyrronium products have a more complex risk profile. Generic applicants must address two active ingredients, dose delivery, inhaler compatibility, and combination-specific claims. These products may retain commercial differentiation after the standalone molecule becomes exposed.
The combination estate is not immune to challenge. Patent invalidity, non-infringement, and skinny-label strategies can reduce the practical value of method-of-use patents. A generic entrant can seek approval for COPD maintenance indications while omitting protected uses where permitted by the regulatory pathway.
Which companies are challenging or competing with indacaterol?
The main competitive threat comes from alternative inhaled maintenance therapies rather than direct indacaterol-only copies.
| Company |
Competing products or classes |
Competitive effect |
| GlaxoSmithKline |
Anoro Ellipta, Trelegy Ellipta, Breo Ellipta |
Strong once-daily LAMA/LABA and triple-therapy competition |
| AstraZeneca |
Bevespi, Breztri, Symbicort |
Combination inhalers and established respiratory prescriber base |
| Boehringer Ingelheim |
Spiriva, Stiolto, Spiolto |
Strong LAMA and LAMA/LABA franchise |
| Viatris and partners |
Advair and generic respiratory products |
Price pressure and broad payer coverage |
| Teva |
ProAir, other inhaled products |
Generic and respiratory portfolio competition |
| Cipla and regional manufacturers |
Inhaled generics and local combinations |
Lower-cost competition in emerging markets |
Indacaterol’s once-daily dosing is commercially useful, but once-daily dosing is no longer unique. Trelegy, Anoro, Stiolto, Breztri, and other products compete on dosing frequency, lung-function improvement, exacerbation reduction, device usability, and payer contracts.
What formulations are protected by indacaterol patents?
The commercially important formulation is a dry-powder inhaler using a single-dose capsule. The capsule is pierced inside the device, and the patient inhales the powder through the inhaler airflow path.
Protection may extend to:
- Particle-size distribution.
- Lactose or other carrier systems.
- Indacaterol maleate concentration.
- Capsule fill weight.
- Delivered-dose uniformity.
- Moisture control and powder stability.
- Inhaler resistance and airflow.
- Dose-counter and capsule-piercing mechanisms.
These claims create technical hurdles but do not prevent all competition. A generic company can develop an alternative dry-powder formulation or a different inhaler, subject to regulatory demonstration. The key barrier is reproducible pulmonary delivery, not simply chemical manufacture of indacaterol maleate.
What patent litigation affects indacaterol products?
Indacaterol litigation has been less commercially prominent than litigation involving major US inhalers such as Advair, Spiriva, Symbicort, and Trelegy. The reason is the relatively limited US revenue base of Arcapta and the absence of a large standalone blockbuster market.
Potential disputes focus on:
- Orange Book-listed patents.
- Infringement of formulation and device claims.
- Paragraph IV certifications.
- Combination-product patents.
- Regulatory exclusivity for inhaled generic products.
- Patent settlements governing launch dates.
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. The brand owner could file an infringement action within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to litigation developments. [6]
No broad public evidence establishes a major current Paragraph IV campaign against indacaterol maleate comparable to the litigation histories of certain high-revenue inhaled products. The commercial consequences of any challenge would be greater for an indacaterol-containing combination than for Arcapta alone.
How has indacaterol’s financial trajectory developed?
Indacaterol-specific revenue is not separately reported in Novartis public financial statements. Novartis reports respiratory products within broader business categories and does not provide a standalone global revenue line for indacaterol maleate, Onbrez, Ultibro, or every regional combination. [5]
The financial trajectory can nevertheless be divided into four stages.
2009-2013: launch and geographic expansion
Onbrez established indacaterol in Europe and other markets. Arcapta entered the United States in 2011. The central value proposition was once-daily LABA dosing, which differentiated indacaterol from older twice-daily therapies.
2013-2017: combination-product expansion
Ultibro and Utibron shifted the franchise toward LABA/LAMA treatment. This was strategically important because COPD treatment guidelines increasingly emphasized dual bronchodilation for patients with persistent symptoms. Combination products also raised switching costs and broadened clinical positioning.
2017-2020: competitive and commercial pressure
The market became more crowded. Once-daily products from GSK, Boehringer Ingelheim, and AstraZeneca competed directly on device convenience and clinical outcomes. The US standalone product did not achieve the scale needed to become a major respiratory franchise. Novartis subsequently transferred US rights for several respiratory products to Sun Pharma. [5]
2020 onward: lifecycle management and regional concentration
Indacaterol’s continuing value has depended on international sales and combination products, including triple therapy and asthma products. The commercial center of gravity moved away from standalone LABA treatment and toward branded combination inhalers with differentiated clinical positioning.
How does indacaterol compare with competing LABAs?
| Attribute |
Indacaterol |
Salmeterol |
Formoterol |
Olodaterol |
| Typical dosing |
Once daily |
Twice daily |
Usually twice daily |
Once daily |
| Main use |
COPD, combinations |
COPD and asthma |
COPD and asthma |
COPD |
| Commercial strength |
Combination-focused |
Mature and genericized |
Mature and widely used |
Concentrated in combination products |
| Device dependence |
High |
Product-dependent |
Product-dependent |
High |
| Generic pressure |
Increasing |
High |
High |
Increasing |
| Differentiation |
24-hour bronchodilation and Breezhaler platform |
Established clinical familiarity |
Rapid onset and broad use |
Once-daily dosing |
Indacaterol’s strongest advantage is once-daily COPD maintenance. Its main weakness is that this advantage is shared by newer branded products, while older LABAs have deeper clinical familiarity and lower prices.
What licensing deals affect indacaterol?
The most important disclosed transaction affecting the US commercial position was Novartis’s transfer of US rights for Arcapta Neohaler, Utibron Neohaler, and Seebri Neohaler to Sun Pharmaceutical Industries. The transaction placed commercialization under a company with a broader generic and specialty-pharmaceutical operating model. [5]
The broader indacaterol franchise also relies on regional commercialization arrangements, local registrations, and distribution partnerships. These arrangements are more significant outside the United States, where the Breezhaler platform has wider market access.
What revenue exposure remains for indacaterol?
Revenue exposure is concentrated in:
- European COPD maintenance treatment.
- Fixed-dose LABA/LAMA products.
- Triple therapy for asthma in selected markets.
- Markets where Breezhaler is established with pulmonologists.
- Combination-product reimbursement that supports premium pricing.
Revenue exposure is limited by:
- The lack of a separately reported indacaterol revenue line.
- Declining relevance of standalone LABA therapy.
- Generic pressure on mature inhaled products.
- Payer preference for lower-cost alternatives.
- Regional differences in device substitution and reimbursement.
- Competition from once-daily triple therapies.
The molecule remains commercially relevant as a platform component, but its value is not equivalent to the value of the overall Novartis respiratory franchise.
What generic launch scenarios are most likely?
The most likely launch pathway is staggered rather than simultaneous.
| Scenario |
Likely commercial effect |
| Standalone indacaterol generic |
Low to moderate impact because US branded sales are limited |
| Generic indacaterol/glycopyrronium |
Higher impact in COPD markets if device and combination patents are cleared |
| Alternative-device product |
Delayed entry but potential substitution if regulatory requirements are met |
| Regional generic launch |
Significant price pressure in countries with weak device protection |
| Authorized-generic or rights-holder launch |
Faster payer conversion with lower litigation risk |
A generic launch against a combination product would have the greatest effect on continuing franchise value. A launch against Arcapta alone would likely have less impact because the product’s commercial base is already small.
Key Takeaways
- Indacaterol maleate is a mature once-daily LABA with declining standalone commercial importance.
- The principal value now lies in Ultibro, Utibron, Atectura, and Enerzair-type combination products.
- The US market is commercially weak after the transfer of Arcapta and related respiratory rights to Sun Pharma.
- Patent protection is fragmented across compound, salt, formulation, device, capsule, and combination claims.
- Generic entry risk is greater for standalone indacaterol than for technically complex combination inhalers, but combination products face substantial long-term pressure.
- No public financial disclosure provides a reliable standalone global revenue figure for indacaterol maleate.
- The strongest remaining commercial markets are Europe and selected international territories using the Breezhaler platform.
FAQs
Is indacaterol maleate still sold in the United States?
US availability is limited compared with its European and international presence. Arcapta Neohaler and related products underwent commercial rights changes, and US sales are not the main source of current indacaterol franchise value.
Is indacaterol maleate a biologic?
No. Indacaterol maleate is a small-molecule inhaled bronchodilator. Biosimilar rules do not apply. Competition is governed by small-molecule generic and inhaled-device regulatory pathways.
Does indacaterol treat asthma?
Indacaterol-containing products are used in certain inhaled corticosteroid combinations for asthma in markets where regulators have approved those products. Indacaterol monotherapy is primarily associated with COPD maintenance treatment.
Can a generic use a different indacaterol inhaler?
Potentially. A generic applicant may develop a different device, but it must satisfy applicable FDA or other national requirements for dose delivery, equivalence, labeling, and substitutability. Device patents can delay entry without preventing it permanently.
What is the largest competitive threat to indacaterol?
The largest threat is once-daily combination therapy, especially LAMA/LABA and triple inhalers such as Anoro, Trelegy, Breztri, and related regional products. These products compete on convenience, exacerbation reduction, reimbursement, and established prescriber use.
References
- U.S. Food and Drug Administration. (2011). Arcapta Neohaler (indacaterol maleate) prescribing information.
- U.S. Food and Drug Administration. (2015). Utibron Neohaler (indacaterol/glycopyrrolate) prescribing information.
- European Medicines Agency. (2009). Onbrez Breezhaler: European public assessment report.
- European Medicines Agency. (2013). Ultibro Breezhaler: European public assessment report.
- Novartis AG. (2020). Annual report 2020.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
